检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王丙剑[1] 胡婷婷[1] 耿金[1] 李倩君[1] 施建丽 马树人[1]
机构地区:[1]南京医科大学附属淮安第一医院心脏病科,江苏省223300 [2]南京医科大学附属鼓楼临床医学院心脏病科
出 处:《江苏医药》2015年第15期1777-1780,共4页Jiangsu Medical Journal
基 金:南京医科大学科技发展基金重点项目(2011NJMU241)
摘 要:目的探讨氯吡格雷在急性前壁心肌梗死(MI)患者经皮冠状动脉介入治疗(PCI)的应用效果。方法急性前壁MI行急诊PCI患者160例,随机均分为四组:A组和B组术前氯吡格雷负荷量均为300mg,术后每日维持量分别为75mg和150mg;C组和D组术前负荷量氯吡格雷600mg,术后每日维持量分别为75mg和150mg。随访1个月,观察各组间出血及主要心脏不良事件(MACE)发生情况。结果术前负荷量氯吡格雷300mg组发生MACE的风险大于600mg组[OR=2.46,95%CI(1.04-5.84),P=0.04],而术后维持用氯吡格雷75mg与150mg发生MACE的风险相仿[OR=0.84,95%CI(0.37-1.92),P=0.67]。结论对于急性前壁MI患者,PCI术前应用负荷量氯吡格雷600mg较300mg更能有效减少术后1个月内的MACE发生率。Objective To investigate the efficacy of clopidogrel in the patients with acute anterior myocardial infarction(MI) undergoing percutaneous coronary intervention(PCI). Methods A total of 160 patients with acute anterior MI and undergoing PCI was randomly assigned into four groups. The patients in groups of A and B were given clopidogrel 300 mg before PCI, which was followed by a maintenance dose of 75 mg/d and 150 mg/d, respectively. The patients in groups of C and D were given clopidogrel 600 mg before PCI, which was followed by a maintenance dose of 75 mg/d and 150 rag/d, respectively. All patients were followed up for 30 days and the incidence of bleeding and major adverse cardiovascular events(MACE) were recorded. Results The risk of MACE was higher in groups of A and B than that in groups of C and D [OR = 2. 46,95% CI (1.04-5.84), P=0. 04],which was not significantly different between groups of A and C and groups of B and D FOR= 0.84, 95% CI (0. 37-1.92), P=0. 67)]. Conclusion A loading dose of clopidogrel 600 mg before PCI is more effective in reducing the incidence of MACE in the patients with acute anterior MI undergoing PCI.
关 键 词:急性前壁心肌梗死 经皮冠状动脉介入治疗 氯吡格雷
分 类 号:R541[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222